Literature DB >> 21866324

A comparison of the Sensititre® MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis.

M M Abuali1, R Katariwala, V J LaBombardi.   

Abstract

The agar proportion method (APM) for determining Mycobacterium tuberculosis susceptibilities is a qualitative method that requires 21 days in order to produce the results. The Sensititre method allows for a quantitative assessment. Our objective was to compare the accuracy, time to results, and ease of use of the Sensititre method to the APM. 7H10 plates in the APM and 96-well microtiter dry MYCOTB panels containing 12 antibiotics at full dilution ranges in the Sensititre method were inoculated with M. tuberculosis and read for colony growth. Thirty-seven clinical isolates were tested using both methods and 26 challenge strains of blinded susceptibilities were tested using the Sensititre method only. The Sensititre method displayed 99.3% concordance with the APM. The APM provided reliable results on day 21, whereas the Sensititre method displayed consistent results by day 10. The Sensititre method provides a more rapid, quantitative, and efficient method of testing both first- and second-line drugs when compared to the gold standard. It will give clinicians a sense of the degree of susceptibility, thus, guiding the therapeutic decision-making process. Furthermore, the microwell plate format without the need for instrumentation will allow its use in resource-poor settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21866324     DOI: 10.1007/s10096-011-1382-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Improved recovery of Mycobacterium tuberculosis from children using the microscopic observation drug susceptibility method.

Authors:  Richard A Oberhelman; Giselle Soto-Castellares; Luz Caviedes; Maria E Castillo; Patricia Kissinger; David A J Moore; Carlton Evans; Robert H Gilman
Journal:  Pediatrics       Date:  2006-06-02       Impact factor: 7.124

2.  Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Girum Shiferaw; Yimtubezinash Woldeamanuel; Mekdes Gebeyehu; Feven Girmachew; Daniel Demessie; Eshetu Lemma
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

Review 3.  Extensively drug-resistant tuberculosis: new strains, new challenges.

Authors:  Ritu Banerjee; Gisela F Schecter; Jennifer Flood; Travis C Porco
Journal:  Expert Rev Anti Infect Ther       Date:  2008-10       Impact factor: 5.091

Review 4.  Tuberculosis drug resistance testing by molecular methods: opportunities and challenges in resource limited settings.

Authors:  Gemeda Abebe; Fabienne Paasch; Ludwig Apers; Leen Rigouts; Robert Colebunders
Journal:  J Microbiol Methods       Date:  2010-12-01       Impact factor: 2.363

5.  Rapid detection of multidrug-resistant Mycobacterium tuberculosis by use of real-time PCR and high-resolution melt analysis.

Authors:  Melissa V Ramirez; Kelley C Cowart; Patricia J Campbell; Glenn P Morlock; David Sikes; Jonas M Winchell; James E Posey
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

Review 6.  Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.

Authors:  Suhail Ahmad; Eiman Mokaddas
Journal:  Respir Med       Date:  2009-08-05       Impact factor: 3.415

7.  Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test.

Authors:  Akio Aono; Kazue Hirano; Sonomi Hamasaki; Chiyoji Abe
Journal:  Diagn Microbiol Infect Dis       Date:  2002-12       Impact factor: 2.803

Review 8.  Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis.

Authors:  Freddie Bwanga; Sven Hoffner; Melles Haile; Moses L Joloba
Journal:  BMC Infect Dis       Date:  2009-05-20       Impact factor: 3.090

  8 in total
  17 in total

1.  Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.

Authors:  Scott K Heysell; Suporn Pholwat; Stellah G Mpagama; Saumu J Pazia; Happy Kumburu; Norah Ndusilo; Jean Gratz; Eric R Houpt; Gibson S Kibiki
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

Review 2.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

3.  Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests.

Authors:  Justin L Kandler; Alexandra D Mercante; Tracy L Dalton; Matthew N Ezewudo; Lauren S Cowan; Scott P Burns; Beverly Metchock; Peter Cegielski; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Comparison of TaqMan(®) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB.

Authors:  S Foongladda; S Banu; S Pholwat; J Gratz; S O-Thong; N Nakkerd; R Chinli; S S Ferdous; S M M Rahman; A Rahman; S Ahmed; S Heysell; M Sariko; G Kibiki; E Houpt
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

5.  Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents.

Authors:  Leslie Hall; Kurt P Jude; Shirley L Clark; Kim Dionne; Ryan Merson; Ana Boyer; Nicole M Parrish; Nancy L Wengenack
Journal:  J Clin Microbiol       Date:  2012-08-15       Impact factor: 5.948

6.  Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs.

Authors:  Jongseok Lee; Derek T Armstrong; Willy Ssengooba; Jeong-Ae Park; Yeuni Yu; Francis Mumbowa; Carolyn Namaganda; Gerald Mboowa; Germine Nakayita; Sandra Armakovitch; Gina Chien; Sang-Nae Cho; Laura E Via; Clifton E Barry; Jerrold J Ellner; David Alland; Susan E Dorman; Moses L Joloba
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

7.  Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.

Authors:  Jung-Yien Chien; Shun-Tien Chien; Wei-Yih Chiu; Chong-Jen Yu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.

Authors:  Scott K Heysell; Shahriar Ahmed; Sara Sabrina Ferdous; Md Siddiqur Rahman Khan; S M Mazidur Rahman; Jean Gratz; Md Toufiq Rahman; Asif Mujtaba Mahmud; Eric R Houpt; Sayera Banu
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

9.  A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia.

Authors:  Elena Y Nosova; Danila V Zimenkov; Anastasia A Khakhalina; Alexandra I Isakova; Ludmila Y Krylova; Marina V Makarova; Ksenia Y Galkina; Maria A Krasnova; Svetlana G Safonova; Vitaly I Litvinov; Dmitry A Gryadunov; Elena M Bogorodskaya
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

10.  Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.

Authors:  Stellah G Mpagama; Eric R Houpt; Suzanne Stroup; Happiness Kumburu; Jean Gratz; Gibson S Kibiki; Scott K Heysell
Journal:  BMC Infect Dis       Date:  2013-09-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.